Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20117 plus almonertinib in EGFR-mutant advanced non-squamous NSCLC (Ib/III)
CTR20241728Phase 3Active
- Sponsor
- Changzhou Hengbang Pharmaceutical
- Start
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of PM1080 in non-small cell lung cancer (NSCLC), sponsored by Changzhou Hengbang Pharmaceutical. Started Jun 2024; status: active.
02
Drugs
PM1080
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241728.